Charles River Laboratories International (CRL) Liabilities and Shareholders Equity (2009 - 2026)

Charles River Laboratories International's Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $7.1 billion for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity fell 5.22% year-over-year to $7.1 billion; the TTM figure through Dec 2025 stood at $29.8 billion (down 5.82% YoY), while the FY2025 annual figure was $7.1 billion, down 5.22% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $7.1 billion, down from $7.5 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $8.2 billion in Q4 2023, with the low at $5.8 billion in Q1 2021.
• The 5-year median for Liabilities and Shareholders Equity is $7.5 billion (2022), against an average of $7.4 billion.
• The sharpest annual moves came in 2021 and 2024: Liabilities and Shareholders Equity rose 28.23% in 2021, then decreased 8.13% in 2024.
• Charles River Laboratories International's Liabilities and Shareholders Equity stood at $7.0 billion in 2021, then rose by 8.24% to $7.6 billion in 2022, then grew by 7.79% to $8.2 billion in 2023, then retreated by 8.13% to $7.5 billion in 2024, then decreased by 5.22% to $7.1 billion in 2025.
• Business Quant data shows CRL's Liabilities and Shareholders Equity at $7.1 billion in Q4 2025, $7.5 billion in Q3 2025, and $7.6 billion in Q2 2025.